Related Experiment Videos
Bacterial prostatitis: treatment with carbenicillin indanyl sodium
Investigative Urology
|July 1, 1981
Summary
Carbenicillin indanyl sodium demonstrated high clinical success (93%) and safety in treating bacterial prostatitis. This antibiotic shows promise for patients with resistant infections, warranting further investigation.
Area of Science:
- Infectious Diseases
- Pharmacology
- Urology
Background:
- Bacterial prostatitis presents a significant challenge in antimicrobial therapy.
- Identifying effective treatments for acute and chronic prostatitis is crucial for patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of carbenicillin indanyl sodium in patients with bacterial prostatitis.
- To compare the effectiveness of carbenicillin indanyl sodium against cephalexin in a concurrent treatment group.
Main Methods:
- A study involving 16 patients diagnosed with acute or chronic bacterial prostatitis.
- Patients received carbenicillin indanyl sodium (Geocillin) at 2000 mg four times daily for 14 (acute) or 28 (chronic) days.
- Clinical and bacteriologic outcomes were assessed at a 4-week post-therapy follow-up.
Main Results:
- High clinical success rate of 93% and a bacteriologic success rate of 75% were observed.
- No adverse reactions were reported during the study period.
- Results for the alternative therapy group using cephalexin were generally unsatisfactory.
Conclusions:
- Carbenicillin indanyl sodium is an effective and safe treatment option for bacterial prostatitis.
- The drug shows potential for treating bacterial prostatitis, particularly in populations with resistant infections.
- Further research into carbenicillin indanyl sodium for resistant prostatitis cases is recommended.